Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

COVID-19: UK-based research institute specialising in infectious disease offers support to partners for coronavirus research

Country of Origin: United Kingdom
Reference Number: TOUK20200429002
Publication Date: 29 April 2020

Summary

A UK-based research institute with world recognised expertise in the area of infectious disease research is offering its capabilities to industrial partners as well as universities and research organisations in developing innovations in the diagnosis and treatment of COVID-19. It is envisaged that the partnerships will take the form of research cooperation agreements, technical cooperation agreements or commercial agreements with technical assistance.

Description

The current COVID-19 pandemic is one of the greatest global health crisis ever faced. It will require a transnational and cross-discipline approach to research and innovation to find better diagnostics, new treatments, vaccines and to understand the epidemiology and prognostic factors behind the disease.

A UK-based research institute has world renowned expertise in the area of infectious diseases especially in the rapid translation of infectious diseases research with a primary focus to combat the threats of resistance to public health across the globe. With over 500 researchers the institute has a proven track record working with industry through the whole development pathway and is currently contributing to products currently in clinical development including therapeutics, diagnostics, vaccines, including multiple projects related to COVID-19.

The research institute is offering its capabilities to partner with companies, research institutions and universities working on innovations in coronavirus and COVID-19 research. This can be diagnostics, therapeutics or preventatives measures such as vaccines. The institute will provide partners with access to its knowledge, facilities and capabilities. The institute will use the knowledge transfer resulting from these partnerships to further develop their capabilities and knowledge base.

It is envisaged that the partnerships will take the form of research cooperation agreements, technical cooperation agreements or commercial agreements with technical assistance, depending on the individual circumstances of the partner.

Advantages and Innovations

The UK-based research organisation has the following advantages:

It is internationally recognised for its infectious diseases research with over 500 researchers working directly in this field.

A proven track record working with industry and academia on clinical trials contributing to products currently in clinical development or on the market.

It is curating the UK's biobank of samples from patients with COVID-19.

Has COVID-19 genome sequencing capacity, diagnostics development capacity and is also researching potential small molecule biomarkers and prognostic biomarkers.

They have experience in therapeutics development and expertise in pre-clinical screening.

Their clinical research facility is the first National Health Service (NHS)-led unit in England and Wales to achieve the Medicines & Healthcare products Regulatory Agency (MHRA) Phase I accreditation.

They have experienced teams in the areas of virology, pathogen biology, drug discovery and vaccines development.

Expertise in epidemiology and public health informatics.

This wide ranging experience brings together the different aspects of research and innovation required for addressing the coronavirus pandemic.

Stage Of Development

Already on the market

Requested partner

The UK research institution is looking to partner with companies in particular but also with universities and other research organisations that are developing new diagnostics and treatments for COVID-19.

The UK research institute will provide assistance to the partner in terms of consultation in a wide range of areas including genomics, biomarkers both diagnostic and prognostic, pathogen biology, epidemiology, drug discovery, virology and vaccines.

The UK research institute will use the information generated through these partnerships to further develop its capabilities and expertise and enhance its offer as well as contribute to the research and innovation against coronavirus.

It is expected that the partnerships will take the form of research cooperation agreements, technical cooperation agreements or commercial agreements with technical assistance depending on circumstances.

Cooperation offer ist closed for requests